<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633580</url>
  </required_header>
  <id_info>
    <org_study_id>2012/019</org_study_id>
    <nct_id>NCT01633580</nct_id>
  </id_info>
  <brief_title>D2 Versus D4 Corifollitropin Alfa in GnRH Antagonists</brief_title>
  <official_title>Follicular Phase Endocrine Characteristics During Ovarian Stimulation and GnRH Antagonist Co-treatment for IVF; Randomized Trial Comparing Corifollitropin Alfa (Elonva) Initiated on Cycle Day 2 or 4.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to analyse if corifollitropin alfa, an agent for
      prolonged ovarian stimulation, administered from day 4 can be clinically used instead of day
      2 onwards for a controlled ovarian hyperstimulation (COH) in an antagonist protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Corifollitropin alfa is a new recombinant gonadotrophin with sustained follicle-stimulating
      activity. It offers novel and effective treatment option for potential normal responder
      patients undergoing ovarian stimulation with GnRH antagonist co-treatment for IVF or in vitro
      fertilisation resulting in a high ongoing pregnancy rate, equal to that achieved with daily
      rFSH. Normally, this medication is started on day 2 of the cycle. In the present randomised
      trial, we want to evaluate whether this agent can be clinically used when started on day 4 of
      the cycle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Consumption of rFSH at the end of the follicular phase</measure>
    <time_frame>up to 9 months</time_frame>
    <description>The purpose is to assess the additional need for recFSH in each treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>The purpose is to study the pregnancy rate in each treatment group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Day 2 group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients undergo a standard treatment with a classical start of corifollitropin alfa in a GnRH antagonist protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Day 4 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo an ovarian stimulation, but start on day 4 with corifollitropin alfa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corifollitropin alfa</intervention_name>
    <description>long acting FSH</description>
    <arm_group_label>Day 2 group</arm_group_label>
    <arm_group_label>Day 4 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt; 36 years old on day of randomisation

          -  FSH &lt; 12 (in the early follicular phase)

          -  Normal ultrasound scan, i.e. presence of both ovaries, without evidence of abnormality
             within 6 months prior to randomisation.

          -  Regular menstrual cycles of 21-35 days, presumed to be ovulatory.

          -  BMI ≤ 29

          -  Weight &gt; 60 kg

          -  &lt; 3 previous trials

          -  ICSI

          -  Randomisation at out-patient clinic

        Exclusion Criteria:

          -  ≥ 36 years old on day of randomisation

          -  Endometriosis ≥ grade 3

          -  PCOS

          -  Poor responders (development of &lt; 4 follicles in a previous IVF/ICSI cycle)

          -  Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2012</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitair Ziekenhuis Brussel</investigator_affiliation>
    <investigator_full_name>Blockeel Christophe</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>ICSI</keyword>
  <keyword>GnRH antagonist</keyword>
  <keyword>corifollitropin alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

